Related Experiment Videos
Intravitreal bevacizumab (Avastin) for choroidal neovascularization in angioid streaks: a case series
M Carla Donati1, Gianni Virgili, Alessandro Bini
1Department of Oto-Neuro-Ophthalmological Surgical Sciences, University of Florence, Florence, Italy.
Background:
Intravitreal (IV) bevacizumab (Avastin(R), Roche), initially used for the off-label treatment of neovascular age-related macular degeneration (AMD), has extended itself to treat various ocular pathologies such as choroidal neovascularization not associated to AMD.
Methods:
IV bevacizumab 1,25 mg (Avastin) was used in the treatment of choroidal neovascularization (CNV) in 6 eyes of 5 patients with angioid streaks. All cases had a history of photodynamic treatment (PDT) or laser treatment and all showed progressive worsening despite the use of these therapies.
Results:
After injection patients were followed up at nearly 2-month intervals. IV Avastin was repeated in case of recurrence. Three eyes were treated combining PDT and IV Avastin. Cases were followed up for 7-14 months. All patients needed more IV injections. Five out of 6 eyes showed an improvement of BCVA and a slight reduction of leakage and size with FA.
Conclusion:
This small series suggests that IV Avastin might be useful in the treatment of CNV due to AS.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Diabetic Retinopathy
Glaucoma: Overview